Precision Cancer Care for Community Practitioners: NTRK- and RET-Altered Malignancies

Learn current and emerging best practices for managing NTRK- and RET-altered malignancies with this expert-led meeting series.


  • Overview and Rationale for Testing for NTRK and RET Gene Fusions
  • Clinical Data and Current Indications for TRK Inhibitors
  • Clinical Data and Current Indications for RET Inhibitors
  • Panel Discussion, and Audience Question and Answer Session


Date / Time
Event Details


Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Thomas Stinchcombe, MD

Professor of Medicine
Department of Medicine
Duke University School of Medicine
Member, Duke Cancer Institute
Durham, North Carolina

Mary Jo Fidler, MD

Associate Professor
Rush University Medical Center
Chicago, Illinois

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with NTRK- and RET-altered malignancies.

Target Audience
This program is intended for community medical oncologists, nurses, pharmacists, and other HCPs who treat and manage patients with NTRK- and RET-altered malignancies

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate screening to detect NTRK and RET gene fusions
  • Describe the clinical research data supporting the use of TRK inhibition in NTRK fusion–positive and RET fusion–positive patients across all solid tumors
  • Summarize ongoing research regarding the efficacy and safety of selective RET inhibitors in patients with RET fusion–positive mutations across various tumor types
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients in clinical trials
  • Develop treatment strategies for patients who develop acquired resistance to first-generation TRK and RET inhibitor therapy


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Live UAN: JA4008176-0000-22-028-L01-P

Virtual UAN: JA4008176-0000-22-029-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.